• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    5/22/24 12:31:29 PM ET
    $AHG
    $BDRX
    $CYCN
    $EGRX
    Real Estate
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AHG alert in real time by email

    Gainers

    • IGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million.
    • Akso Health Group (NASDAQ:AHG) stock moved upwards by 21.96% to $1.05. The company's market cap stands at $153.8 million.
    • MultiPlan (NYSE:MPLN) shares rose 18.57% to $0.64. The company's market cap stands at $415.4 million.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 14.61% to $2.98. The company's market cap stands at $7.4 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) shares increased by 12.79% to $1.41. The company's market cap stands at $9.3 million.
    • Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 11.91% to $2.63. The market value of their outstanding shares is at $22.4 million.

    Losers

    • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares declined by 41.2% to $1.37 during Wednesday's regular session. The market value of their outstanding shares is at $7.6 million.
    • Oragenics (AMEX:OGEN) stock fell 36.85% to $1.92. The market value of their outstanding shares is at $8.6 million.
    • LifeStance Health Gr (NASDAQ:LFST) shares decreased by 19.42% to $6.03. The company's market cap stands at $2.3 billion.
    • Mustang Bio (NASDAQ:MBIO) shares decreased by 17.1% to $0.26. The market value of their outstanding shares is at $3.2 million.
    • Eagle Pharmaceuticals (NASDAQ:EGRX) stock fell 16.71% to $3.64. The company's market cap stands at $47.1 million.
    • GT Biopharma (NASDAQ:GTBP) stock decreased by 16.08% to $4.7. The company's market cap stands at $6.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $BDRX
    $CYCN
    $EGRX

    CompanyDatePrice TargetRatingAnalyst
    LifeStance Health Group Inc.
    $LFST
    12/9/2025$8.00Overweight
    Barclays
    LifeStance Health Group Inc.
    $LFST
    11/13/2025$8.00Outperform
    BMO Capital Markets
    LifeStance Health Group Inc.
    $LFST
    7/25/2025$8.00Buy
    BTIG Research
    LifeStance Health Group Inc.
    $LFST
    5/27/2025$8.50Neutral → Buy
    UBS
    LifeStance Health Group Inc.
    $LFST
    4/8/2025$9.00Overweight
    KeyBanc Capital Markets
    LifeStance Health Group Inc.
    $LFST
    4/3/2025$8.00Buy
    Canaccord Genuity
    IGM Biosciences Inc.
    $IGMS
    1/10/2025$21.00 → $2.00Outperform → Market Perform
    BMO Capital Markets
    IGM Biosciences Inc.
    $IGMS
    1/10/2025$12.00 → $2.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $AHG
    $BDRX
    $CYCN
    $EGRX
    SEC Filings

    View All

    Indaptus Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)

    4/3/26 12:00:08 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    4/2/26 4:28:29 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)

    4/2/26 4:28:28 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BDRX
    $CYCN
    $EGRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

    April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form. Commenting, Dan Palmer, Vice President, Technology at Biodexa said "We are delighted to be partnering with Syngene for the s

    4/2/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

    Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases Korsana's lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease Concurrent private financing of approximately $380 million expected to fund Korsana's operations into 2029, including multiple clinical trial data readouts expected in 2027 Conference call scheduled for April 1, 2026, at 8:00 am ET Cyclerion Therapeutics, Inc. ("Cyclerion") (NASDAQ:CYCN) and Korsana Biosciences, Inc. ("Korsana"), a privately-held biotechnology company discovering and developin

    4/1/26 7:05:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BDRX
    $CYCN
    $EGRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Burdick Kenneth A bought $498,294 worth of shares (114,181 units at $4.36), increasing direct ownership by 2% to 3,436,571 units (SEC Form 4)

    4 - LifeStance Health Group, Inc. (0001845257) (Issuer)

    8/12/25 4:30:22 PM ET
    $LFST
    Medical/Nursing Services
    Health Care

    SVP, Chief Information Officer Kim Michael bought $249,588 worth of shares (40,000 units at $6.24), increasing direct ownership by 3% to 1,312,772 units (SEC Form 4)

    4 - MultiPlan Corp (0001793229) (Issuer)

    11/19/24 4:35:27 PM ET
    $MPLN
    Business Services
    Consumer Discretionary

    $AHG
    $BDRX
    $CYCN
    $EGRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on LifeStance Health Group with a new price target

    Barclays initiated coverage of LifeStance Health Group with a rating of Overweight and set a new price target of $8.00

    12/9/25 8:50:31 AM ET
    $LFST
    Medical/Nursing Services
    Health Care

    BMO Capital Markets initiated coverage on LifeStance Health Group with a new price target

    BMO Capital Markets initiated coverage of LifeStance Health Group with a rating of Outperform and set a new price target of $8.00

    11/13/25 9:14:47 AM ET
    $LFST
    Medical/Nursing Services
    Health Care

    BTIG Research initiated coverage on LifeStance Health Group with a new price target

    BTIG Research initiated coverage of LifeStance Health Group with a rating of Buy and set a new price target of $8.00

    7/25/25 9:06:51 AM ET
    $LFST
    Medical/Nursing Services
    Health Care

    $AHG
    $BDRX
    $CYCN
    $EGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pardo Ryan

    4 - LifeStance Health Group, Inc. (0001845257) (Issuer)

    4/3/26 6:49:02 PM ET
    $LFST
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Yao Yun

    3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    4/2/26 7:18:19 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Sino Lion Ventures Ltd

    3 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

    4/2/26 7:16:54 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BDRX
    $CYCN
    $EGRX
    Leadership Updates

    Live Leadership Updates

    View All

    Preliminary Results for the Year Ended 31 December 2025

    March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma

    3/27/26 5:00:00 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BDRX
    $CYCN
    $EGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Indaptus Therapeutics Inc.

    SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

    11/26/24 4:11:08 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BDRX
    $CYCN
    $EGRX
    Financials

    Live finance-specific insights

    View All

    Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

    Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases Korsana's lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease Concurrent private financing of approximately $380 million expected to fund Korsana's operations into 2029, including multiple clinical trial data readouts expected in 2027 Conference call scheduled for April 1, 2026, at 8:00 am ET Cyclerion Therapeutics, Inc. ("Cyclerion") (NASDAQ:CYCN) and Korsana Biosciences, Inc. ("Korsana"), a privately-held biotechnology company discovering and developin

    4/1/26 7:05:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeStance to Host Fourth Quarter and Full Year 2025 Earnings Conference Call on February 25, 2026

    SCOTTSDALE, Ariz., Feb. 09, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its fourth quarter and full year 2025 earnings release before the market opens on Wednesday, February 25, 2026. LifeStance will host a live earnings conference call to discuss fourth quarter and full year results on February 25, 2026, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 3993891, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentat

    2/9/26 4:10:00 PM ET
    $LFST
    Medical/Nursing Services
    Health Care

    Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced that its Board of Directors (the "Board") has adopted an amendment (the "Amendment") to its existing limited duration stockholder rights plan (as amended, the "Rights Plan") to extend the duration of the Rights Plan by one year to October 30, 2026, effective immediately. The amendment to the Rights Plan was adopted in response to the ongoing significant dislocation in the trading price of the Company's common stock. The amendment will have the effect of increasing the potential dilution an Acquiring Person would potentially face if the Rights Plan were

    10/30/25 6:50:00 AM ET
    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care